Crosstalk between miRNAs and signaling pathways in the development of drug resistance in breast cancer.

IF 1.1 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY
Reza Amiri, Poorya Najjari Nabi, Ahmad Fazilat, Fatemeh Roshani, Alireza Nouhi Kararoudi, Mohsen Hemmati-Dinarvand, Mohammad Valilo
{"title":"Crosstalk between miRNAs and signaling pathways in the development of drug resistance in breast cancer.","authors":"Reza Amiri, Poorya Najjari Nabi, Ahmad Fazilat, Fatemeh Roshani, Alireza Nouhi Kararoudi, Mohsen Hemmati-Dinarvand, Mohammad Valilo","doi":"10.1515/hmbci-2024-0066","DOIUrl":null,"url":null,"abstract":"<p><p>One of the biggest challenges of today's society is cancer, which imposes a significant financial, emotional and spiritual burden on human life. Breast cancer (BC) is one of the most common cancers that affects people in society, especially women, and due to advanced treatment strategies and primary prevention, it is still the second cause of cancer-related deaths in society. Various genetic and environmental factors are involved in the development of BC. MicroRNAs (miRNA)s are non-coding RNAs, that the degradation or inhibition of them plays an important role in the prevention or development of cancer by modulating many cellular pathways including apoptosis, drug resistance, and tumorigenesis. Drug resistance is one of the important defense mechanisms of cancer cells against anticancer drugs and is considered one of the main causes of cancer treatment failure. Different miRNAs, including mir-7, mir-21, mir-31, and mir-124 control different cell activities, including drug resistance, through different pathways, including PI3K/AKT/mTOR, TGF-β, STAT3, and NF-kB. Therefore, cell signaling pathways are one of the important factors that miRNAs control cellular activities. Hence, in this study, we decided to highlight an overview of the relationship between miRNAs and signaling pathways in the development of drug resistance in BC.</p>","PeriodicalId":13224,"journal":{"name":"Hormone Molecular Biology and Clinical Investigation","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormone Molecular Biology and Clinical Investigation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/hmbci-2024-0066","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

One of the biggest challenges of today's society is cancer, which imposes a significant financial, emotional and spiritual burden on human life. Breast cancer (BC) is one of the most common cancers that affects people in society, especially women, and due to advanced treatment strategies and primary prevention, it is still the second cause of cancer-related deaths in society. Various genetic and environmental factors are involved in the development of BC. MicroRNAs (miRNA)s are non-coding RNAs, that the degradation or inhibition of them plays an important role in the prevention or development of cancer by modulating many cellular pathways including apoptosis, drug resistance, and tumorigenesis. Drug resistance is one of the important defense mechanisms of cancer cells against anticancer drugs and is considered one of the main causes of cancer treatment failure. Different miRNAs, including mir-7, mir-21, mir-31, and mir-124 control different cell activities, including drug resistance, through different pathways, including PI3K/AKT/mTOR, TGF-β, STAT3, and NF-kB. Therefore, cell signaling pathways are one of the important factors that miRNAs control cellular activities. Hence, in this study, we decided to highlight an overview of the relationship between miRNAs and signaling pathways in the development of drug resistance in BC.

乳腺癌耐药发展中mirna与信号通路间的串扰
当今社会最大的挑战之一是癌症,它给人类生活带来了巨大的经济、情感和精神负担。乳腺癌(BC)是影响社会人群,特别是妇女的最常见癌症之一,由于先进的治疗策略和初级预防,它仍然是社会中癌症相关死亡的第二大原因。多种遗传和环境因素参与了BC的发展。MicroRNAs (miRNA)是一种非编码rna,其降解或抑制通过调节细胞凋亡、耐药和肿瘤发生等多种细胞通路,在癌症的预防或发展中起着重要作用。耐药是癌细胞对抗癌药物的重要防御机制之一,被认为是癌症治疗失败的主要原因之一。不同的mirna,包括mir-7、mir-21、mir-31和mir-124,通过不同的途径,包括PI3K/AKT/mTOR、TGF-β、STAT3和NF-kB,控制不同的细胞活性,包括耐药。因此,细胞信号通路是mirna控制细胞活动的重要因素之一。因此,在本研究中,我们决定重点概述mirna和信号通路在BC耐药发展中的关系。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Hormone Molecular Biology and Clinical Investigation
Hormone Molecular Biology and Clinical Investigation BIOCHEMISTRY & MOLECULAR BIOLOGY-
CiteScore
2.60
自引率
0.00%
发文量
55
期刊介绍: Hormone Molecular Biology and Clinical Investigation (HMBCI) is dedicated to the provision of basic data on molecular aspects of hormones in physiology and pathophysiology. The journal covers the treatment of major diseases, such as endocrine cancers (breast, prostate, endometrium, ovary), renal and lymphoid carcinoma, hypertension, cardiovascular systems, osteoporosis, hormone deficiency in menopause and andropause, obesity, diabetes, brain and related diseases, metabolic syndrome, sexual dysfunction, fetal and pregnancy diseases, as well as the treatment of dysfunctions and deficiencies. HMBCI covers new data on the different steps and factors involved in the mechanism of hormone action. It will equally examine the relation of hormones with the immune system and its environment, as well as new developments in hormone measurements. HMBCI is a blind peer reviewed journal and publishes in English: Original articles, Reviews, Mini Reviews, Short Communications, Case Reports, Letters to the Editor and Opinion papers. Ahead-of-print publishing ensures faster processing of fully proof-read, DOI-citable articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信